BiBBInstruments AB (publ) ("BiBBInstruments" or the "Company") hereby announces, in connection with the recently completed rights issue in the Company, that the shareholding of Life Science Invest Fund 1 ApS (LSIF) in the Company will exceed the notification thresholds of 5 and 10 percent of the total number of shares and votes in the Company, and that the shareholding of CHWA AB in the Company will fall below the notification threshold of 5 percent of the total number of shares and votes in the Company, once the shares from the rights issue have been registered with the Swedish Companies Registration Office (Bolagsverket) and Euroclear, based on the Company's knowledge. The shareholding notification is published in accordance with Spotlight Stock Market's notification rules.
Jan Poulsen, CEO of LSIF, comments: "When we took on the role as lead investor in this funding round, we had already decided that we wanted to significantly increase our ownership stake, and we are pleased to become the largest shareholder in BiBB. Unlike many other guarantors, we have no plans to dispose of our shares in the short term, as we strongly believe in the upside potential of BiBB. Raising more than SEK 40 million is substantial for a company of BiBB's size, and we see this as a clear vote of confidence. It will enable BiBB to execute on its business plan towards profitability without diverting management resources to additional financing, as we believe this funding has clear potential to be the last one needed to reach break-even. We have high expectations for BiBB in 2026 and 2027 and look forward to maintaining a close dialogue with the company."
Background and reason for the notifications
LSIF will, as a result of the completed rights issue, exceed the notification thresholds of 5 and 10 percent of the total number of shares and votes in the Company once the shares from the rights issue have been registered with the Swedish Companies Registration Office and Euroclear.
CHWA AB will, as a result of the completed rights issue, fall below the notification threshold of 5 percent of the total number of shares and votes in the Company once the shares from the rights issue have been registered with the Swedish Companies Registration Office and Euroclear.
Shareholding information
The total number of shares and votes in BiBBInstruments amounts to 40,739,302 as of the date of this shareholding notification. After the shares in the rights issue have been registered with the Swedish Companies Registration Office and Euroclear, the total number of shares and votes in BiBBInstruments will amount to 153,983,152.
LSIF
Number of shares and votes in BiBBInstruments prior to the rights issue amounted to 1,337,475, corresponding to 3.3 percent of the total number of shares and votes in the Company.
Number of shares and votes in BiBBInstruments after the rights issue will amount to 17 923 626, corresponding to 11.6 percent of the total number of shares and votes in the Company.
CHWA AB
Number of shares and votes in BiBBInstruments prior to the rights issue amounted to 3,540,000, corresponding to 8.7 percent of the total number of shares and votes in the Company.
Number of shares and votes in BiBBInstruments after the rights issue will amount to 3,742,702, corresponding to 2.4 percent of the total number of shares and votes in the Company.
For more information, please contact:
Fredrik Lindblad, CEO
Email: fredrik.lindblad@bibbinstruments.com
Phone: +46 70 899 94 86
The information was submitted for publication, through the agency of the contact persons set out above, at the time specified by the Company's news distributor at the time of publication of this press release.
About BiBBInstruments AB
BiBBInstruments AB is a cancer diagnostics company that develops and manufactures EndoDrill®, the world's first series of market-cleared electrically driven endoscopic biopsy instruments. EndoDrill® is designed to obtain core tissue samples (core needle biopsies, CNB) with high diagnostic accuracy and aims to improve the diagnosis of cancer in, among others, the stomach, pancreas, liver, lungs, and urinary bladder. The product portfolio targets the global market for ultrasound-guided endoscopic biopsy instruments (EUS/EBUS), one of the most advanced and fastest-growing segments of modern endoscopy. BiBB received FDA 510(k) clearance for its first instrument, EndoDrill® GI, in 2023 and CE marking under the EU Medical Device Regulation (MDR) in 2024 for all three product variants - EndoDrill® GI, EndoDrill® EBUS and EndoDrill® URO. EndoDrill® is thereby the first electrically driven biopsy system approved in both the US and Europe. The US launch of EndoDrill® GI commenced in autumn 2025 in collaboration with TaeWoong Medical USA. The EndoDrill® system consists of sterile single-use instruments and a proprietary drive system. BiBB was founded in 2013 by Dr Charles Walther, cancer researcher at Lund University and senior consultant in clinical pathology at Skåne University Hospital. The Company is headquartered at Medicon Village in Lund and is listed on Spotlight Stock Market (ticker: BIBB).